1. Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
   A.S. Pal et al, 2021, Biochemical Pharmacology CrossRef
2. Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer
   Irlanda Peralta-Arrieta et al, 2022, European Journal of Cancer CrossRef
3. Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
   Chih‐Hsun Wu et al, 2019, Cancer Medicine CrossRef
4. Application of Evidence-Based Nursing Intervention in the Treatment of Advanced Squamous Cell Carcinoma of the Lung by Erlotinib Combined with Tegafur, Gimeracil, and Oteracil Potassium and Its Influence on Quality of Life
   Shan Liu et al, 2021, Journal of Healthcare Engineering CrossRef
5. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer
   Mi-So Jeong et al, 2021, International Journal of Molecular Sciences CrossRef
6. Synergistic antitumor activity of aspirin and erlotinib: Inhibition of p38 enhanced aspirin plus erlotinib‑induced suppression of metastasis and promoted cancer cell apoptosis
   Xiu Hu et al, 2018, Oncology Letters CrossRef
7. Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
   Bingjie Fu et al, 2022, Frontiers in Pharmacology CrossRef